SMG9: A Protein Target for Cancer Treatment and Prevention (G56006)

Target Name: SMG9

NCBI ID: G56006

SMG9

SMG9: A Protein Target for Cancer Treatment and Prevention

Introduction

Several types of cancer have become increasingly common in recent years, leading to a significant impact on public health. The development of new treatments and their effectiveness are crucial for improving the treatment outcomes for cancer patients. One promising approach for cancer treatment is to target the proteins that are over-expressed or mutated in cancer cells, leading to the inhibition of their functions. SMG9, a protein that has been identified as a potential drug target and biomarker for cancer, is a promising candidate for cancer treatment and prevention.

SMG9: Structure and Function

SMG9 is a 21-kDa protein that is expressed in various tissues, including muscle, heart, brain, and organs. It is composed of a unique N-terminal transmembrane domain, a catalytic C-terminal region, and a unique C -terminal region that contains a leucinerich repeat. SMG9 functions as a protein kinase, activating several cellular signaling pathways, including the PI3K/Akt signaling pathway, TGF-灏? signaling pathway, and the NF-kappa-B signaling pathway.

SMG9 is a critical regulator of cell signaling pathways, and its dysfunction has been implicated in various diseases, including cancer. It has been shown to play a role in the regulation of cell adhesion, migration, and invasion. In In addition, SMG9 has been shown to be involved in the regulation of cell survival and apoptosis.

SMG9 as a Drug Target

SMG9 has been identified as a potential drug target due to its unique structure and function. The N-terminal transmembrane domain of SMG9 provides a potential binding site for small molecules, making it an attractive target for drug development. Several studies have shown that SMG9 can be inhibited by small molecules, such as inhibitors of the PI3K/Akt signaling pathway, TGF-灏? signaling pathway, and NF-kappa-B signaling pathway (8, 9).

In addition, SMG9 has been shown to be involved in multiple signaling pathways, making it a versatile target for drug development. For example, SMG9 has been shown to be involved in the regulation of cell adhesion, migration, and invasion, making it an attractive target for anti-cancer drugs that target these pathways. Additionally, SMG9 has been shown to be involved in the regulation of cell survival and apoptosis, making it an attractive target for anti-cancer drugs that target these pathways.

SMG9 as a Biomarker

SMG9 has also been identified as a potential biomarker for cancer. The over-expression of SMG9 has been shown to be associated with the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that the levels of SMG9 have been significantly increased in the blood and tissue of cancer patients, making it an attractive biomarker for cancer diagnosis and monitoring.

Conclusion

SMG9 is a protein that has been identified as a potential drug target and biomarker for cancer. Its unique structure and function make it an attractive target for drug development, and its involvement in multiple signaling pathways makes it a versatile target for cancer treatment and prevention. Further studies are needed to fully understand the role of SMG9 in cancer and to develop effective treatments based on its unique properties.

Protein Name: SMG9 Nonsense Mediated MRNA Decay Factor

Functions: Involved in nonsense-mediated decay (NMD) of mRNAs containing premature stop codons (PubMed:19417104). Is recruited by release factors to stalled ribosomes together with SMG1 and SMG8 (forming the SMG1C protein kinase complex) and, in the SMG1C complex, is required for the efficient association between SMG1 and SMG8 (PubMed:19417104). Plays a role in brain, heart, and eye development (By similarity)

The "SMG9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMG9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets